» Articles » PMID: 25230213

Dysregulated MicroRNA Expression in Adenocarcinoma of the Uterine Cervix: Clinical Impact of MiR-363-3p

Overview
Journal Gynecol Oncol
Date 2014 Sep 18
PMID 25230213
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Adenocarcinoma (ACA) of the uterine cervix is increasing in incidence and currently accounts for approximately 20% of all cervical malignancies. MicroRNAs (miRNAs) have been investigated as potential biomarkers of cervical cancer; however, their role in ACA remains unknown. Here, we characterized miRNA expression profiles and investigated miRNAs as diagnostic and prognostic factors in ACA.

Methods: Evaluation of genome-wide miRNA expression profiles in ACA by microarray led to the identification of ten candidate miRNAs, whose expression patterns were validated by qRT-PCR in 45 ACA, 10 normal control, and 15 squamous cell carcinoma samples. The association between miRNA expression and prognosis was analyzed in patients with ACA.

Results: Microarray analysis identified 86 miRNAs that were dysregulated more than 2.0-fold (p<0.05) in ACA relative to normal tissues of the uterine cervix. Five most over- and underexpressed miRNAs were selected respectively and their expression patterns were confirmed in the validation set. MiR-135b, miR-192, and miR194 were overexpressed in ACA, and miR-363-3p, miR-195 and miR-199b were significantly associated with conventional prognostic factors. Overexpression of miR-363-3p by more than 2.5-fold relative to the normal control was a strong predictor of favorable prognosis (hazard ratio, 0.1; 95% confidence interval, 0.009-0.779) after adjusting for confounders.

Conclusions: MiR-135b, miR-192, and miR-194 are altered in uterine cervical ACA, and miR-363-3p is an independent favorable prognostic factor in ACA. These miRNAs could be of value as biomarkers for the diagnosis and prognosis of ACA.

Citing Articles

Analysis of miR-497/195 cluster identifies new therapeutic targets in cervical cancer.

Karunakara S, Eswaran S, Mallya S, Suresh P, Chakrabarty S, Kabekkodu S BMC Res Notes. 2024; 17(1):217.

PMID: 39095857 PMC: 11297691. DOI: 10.1186/s13104-024-06876-8.


The diagnostic accuracy of serum and plasma microRNAs in detection of cervical intraepithelial neoplasia and cervical cancer: A systematic review and -analysis.

Ssedyabane F, Obuku E, Namisango E, Ngonzi J, Castro C, Lee H Gynecol Oncol Rep. 2024; 54:101424.

PMID: 38939506 PMC: 11208915. DOI: 10.1016/j.gore.2024.101424.


MicroRNA-363-3p inhibits colorectal cancer progression by targeting interferon-induced transmembrane protein 1.

Wang Y, Bai S, Zhang T, Liao C World J Gastrointest Oncol. 2023; 15(9):1556-1566.

PMID: 37746648 PMC: 10514722. DOI: 10.4251/wjgo.v15.i9.1556.


The diagnostic accuracy of serum microRNAs in detection of cervical cancer: a systematic review protocol.

Ssedyabane F, Niyonzima N, Ngonzi J, Tusubira D, Ocan M, Akena D Diagn Progn Res. 2023; 7(1):4.

PMID: 36721194 PMC: 9887905. DOI: 10.1186/s41512-023-00142-4.


Role of microRNAs in Predicting the Prognosis of Cervical Cancer Cases: A Systematic Review and Meta-Analysis.

Sabeena S, Ravishankar N Asian Pac J Cancer Prev. 2021; 22(4):999-1006.

PMID: 33906290 PMC: 8325113. DOI: 10.31557/APJCP.2021.22.4.999.